Imipenem

Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.

Also Known As:

Networked: 1203 relevant articles (163 outcomes, 143 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Pachón, J: 10 articles (05/2013 - 04/2000)
2.	Pichardo, C: 9 articles (07/2011 - 04/2000)
3.	Giacometti, Andrea: 7 articles (12/2013 - 07/2002)
4.	Cirioni, Oscar: 7 articles (12/2013 - 07/2002)
5.	Pachón-Ibáñez, M E: 7 articles (07/2011 - 10/2004)
6.	Caillon, Jocelyne: 6 articles (09/2014 - 10/2004)
7.	Potel, Gilles: 6 articles (09/2014 - 10/2004)
8.	Ghiselli, Roberto: 6 articles (12/2013 - 07/2002)
9.	García-Curiel, A: 6 articles (07/2011 - 04/2000)
10.	Jiménez-Mejías, M E: 6 articles (05/2010 - 04/2000)

Related Diseases

1.	Infection 04/01/2005 - "Imipenem seems to be the most effective agent for the therapy and control of the spread of infections caused by ESBL-producing bacteria. " 01/01/1991 - "The intramuscular imipenem formulation has been proven to be effective for mild to moderate infections of many body sites, as demonstrated by other papers in this symposium. " 04/04/1990 - "These good or very good clinical results show that imipenem is effective in the treatment of severe infections observed in intensive care units." 01/01/2010 - "Imipenem on its own showed no difference in the incidence of mortality, but there was a significant reduction in the rate of pancreatic infection (p=0.02; RR 0.34, 95% CI 0.13 to 0.84). " 12/01/1998 - "Imipenem proved significantly more effective in prevention of pancreatic infections (P </= 0.05). "
2.	Pneumonia (Pneumonitis) 06/01/2014 - "A case of pneumonia caused by Legionella pneumophila serogroup 12 and treated successfully with imipenem." 04/01/2003 - "Our modified rapid imipenem desensitization protocol was successful and allowed for effective treatment of life-threatening pneumonia." 06/15/1998 - "Low dose imipenem could be effective and safe in uncomplicated cases without pneumonia. " 01/01/2010 - "Of the 46 studies identified, 20 (N = 4,310) included patients with pneumonia (imipenem 1,667, PA 251; comparator 1,661, PA 270). " 01/01/2010 - "We conducted a systematic literature review of randomized controlled trials (RCT) of imipenem treatment for pneumonia published in English between 1993 and 2008. "
3.	Sepsis (Septicemia) 05/01/1988 - "Those results demonstrate the efficacy of imipenem in the treatment of septicemia in newborns due to multiresistant Gram negative bacteria." 07/01/1985 - "Efficacy of imipenem was shown in animal models, including septicemia in normal and neutropenic rodents and P. " 05/01/2015 - "The clearance rate of imipenem is increased significantly in vitro under the mode of CVVH with the actual dose of replacement fluid was (31.63±1.48) mL×kg⁻¹×h⁻¹ in severe infective patients with severe sepsis complicating AKI, affecting the level of plasma drug concentration, need to adjust the dosage regimen. " 07/01/2014 - "This epidemic clonal group was more frequently resistant to imipenem and was associated with an increased risk of sepsis, although not with severe sepsis or mortality. " 01/01/2013 - "Impact of imipenem treatment on colonic mycobiota in rats with double-hit sepsis."
4.	Endophthalmitis (Ophthalmia) 01/01/2014 - "The purpose of this paper is to report outcomes of intravitreal imipenem in the treatment of multidrug-resistant Klebsiella-related postoperative endophthalmitis. " 04/01/2012 - "Experimental rabbit endophthalmitis model caused by imipenem resistant A. " 07/01/2002 - "Prophylactic intravenous imipenem can prevent or significantly reduce the severity of experimental endophthalmitis." 07/01/2002 - "Intravenous imipenem prophylaxis in experimental endophthalmitis." 04/01/1994 - "These levels were above the minimum inhibitory concentration of imipenem for 90% (MIC 90) of the main species responsible for endophthalmitis."
5.	Endocarditis 05/01/1992 - "Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis." 01/01/1992 - "Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem." 10/01/1987 - "Hospital acquired native valve endocarditis caused by Acinetobacter calcoaceticus and treated with imipenem/cilastin." 05/01/1986 - "Imipenem was evaluated for its activity against Staphylococcus epidermidis in vitro and in a rabbit model of endocarditis. " 05/01/1986 - "Imipenem therapy of experimental Staphylococcus epidermidis endocarditis."

Related Drugs and Biologics

1.	meropenem (Merrem)
2.	Cilastatin
3.	Ceftazidime (Fortum)
4.	Amikacin (A.M.K)
5.	Vancomycin
6.	Ciprofloxacin (Cipro)
7.	Rifampin (Rifampicin)
8.	Cefotaxime (Kendrick)
9.	Piperacillin
10.	cefepime (Maxipime)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intensive Care (Surgical Intensive Care)
3.	Aftercare (After-Treatment)
4.	Artificial Respiration (Mechanical Ventilation)
5.	Continuous Ambulatory Peritoneal Dialysis (CAPD)